THE MRC-AZ-UNIVERSITY OF CAMBRIDGE JOINT FUNCTIONAL GENOMICS SCREENING LABORATORY (FGSL)

The FGSL – a joint venture between our Institute at the University of Cambridge, the Medical Research Council (MRC) and AstraZeneca – aims to combine know-how and experience to accelerate the development of biomarkers and therapeutics for diseases through functional interrogation of the genome at scale. As part of the Human Functional Genomics Initiative,  the FGSL will form collaborations to explore how genes impact on complex phenotypes in development and disease. Hosted at our Institute as a cross-functional partnership, this laboratory aligns with our mission to combine the strengths of academia and business to accelerate the development of therapies.

The FGSL leverages the unique features of arrayed screening, whereby individual genes are edited via CRISPR/Cas9 in a plate-based format, to uncover the complexity of developmental and disease signatures using human in vitro models. To do this, the laboratory is equipped with a high-throughput screening platform that enables automated liquid handling and acquisition of high-content endpoints including spatial imaging and flow cytometry.

Funding is available for academic researchers from across the UK to access this state-of-the-art automated platform and in-house tools, to perform high-throughput phenotypic screening. A call for proposals for the FGSL is currently open, and further details can be found below.

The FGSL – a joint venture between our Institute at the University of Cambridge, the Medical Research Council (MRC) and AstraZeneca – aims to combine know-how and experience to accelerate the development of biomarkers and therapeutics for diseases through functional interrogation of the genome at scale. As part of the Human Functional Genomics Initiative,  the FGSL will form collaborations to explore how genes impact on complex phenotypes in development and disease. Hosted at our Institute as a cross-functional partnership, this laboratory aligns with our mission to combine the strengths of academia and business to accelerate the development of therapies.

The FGSL leverages the unique features of arrayed screening, whereby individual genes are edited via CRISPR/Cas9 in a plate-based format, to uncover the complexity of developmental and disease signatures using human in vitro models. To do this, the laboratory is equipped with a high-throughput screening platform that enables automated liquid handling and acquisition of high-content endpoints including spatial imaging and flow cytometry.

Funding is available for academic researchers from across the UK to access this state-of-the-art automated platform and in-house tools, to perform high-throughput phenotypic screening. A call for proposals for the FGSL is currently open, and further details can be found below.

FGSL Leadership

Call for Proposals

More about the FGSL

FGSL Partners